Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 6
1979 2
1980 1
1981 2
1982 2
1985 4
1986 2
1987 1
1988 3
1989 3
1990 2
1991 4
1992 2
1993 4
1994 5
1995 6
1996 6
1997 3
1998 4
1999 2
2000 3
2001 3
2002 6
2003 4
2004 3
2005 6
2006 5
2007 7
2008 3
2009 8
2010 6
2011 4
2012 9
2013 4
2014 4
2015 4
2016 1
2017 3
2018 4
2019 3
2020 9
2021 5
2022 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
The COVID-19 social media infodemic.
Cinelli M, Quattrociocchi W, Galeazzi A, Valensise CM, Brugnoli E, Schmidt AL, Zola P, Zollo F, Scala A. Cinelli M, et al. Among authors: zola p. Sci Rep. 2020 Oct 6;10(1):16598. doi: 10.1038/s41598-020-73510-5. Sci Rep. 2020. PMID: 33024152 Free PMC article.
Follow-up in Gynecological Malignancies: A State of Art.
Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, Reed N, Kesic V. Zola P, et al. Int J Gynecol Cancer. 2015 Sep;25(7):1151-64. doi: 10.1097/IGC.0000000000000498. Int J Gynecol Cancer. 2015. PMID: 26207784 Review.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: zola p. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
The role of HE4 in ovarian cancer follow-up: a review.
Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, Landoni F, Gadducci A, Sartori E, Gion M, Zola P. Piovano E, et al. Among authors: zola p. Int J Gynecol Cancer. 2014 Oct;24(8):1359-65. doi: 10.1097/IGC.0000000000000218. Int J Gynecol Cancer. 2014. PMID: 25054447 Free article. Review.
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH, Zola P. van der Zee AG, et al. Among authors: zola p. Int J Gynecol Cancer. 2012 Jan;22(1):175. doi: 10.1097/IGC.0b013e3182261f15. Int J Gynecol Cancer. 2012. PMID: 22193647 No abstract available.
167 results